Before you vote › Federal bills

H.R. 4273: Over-the-Counter Monograph Drug User Fee Amendments

119th Congress · introduced 2025-07-02 · Health · Latest: Placed on the Union Calendar, Calendar No. 254.

federal

Save to my notebook What does this mean? Print

Official title

Over-the-Counter Monograph Drug User Fee Amendments

Plain summary

Over-the-Counter Monograph Drug User Fee Amendments This bill reauthorizes the Over-the-Counter (OTC) Monograph Drug User Fee Program (OMUFA) through FY2030 and revises certain aspects of the program, including total fees to be collected and fee due dates. Under current law, many OTC drugs are marketed through compliance with an OTC monograph issued by the Food and Drug Administration (FDA), rather than through an approved new drug application. Monographs establish the conditions under which OTC drugs are generally recognized as safe and effective, and include ingredients, dosages, and other requirements. OMUFA permits the FDA to collect fees from OTC drug facilities and entities requesting changes to a monograph. The bill makes certain changes to OMUFA, including by revising the total facility fee revenue amount to be collected for FY2026-FY2030, revising due dates for facility fees, permitting the FDA to implement a one-time adjustment to facility fees if certain conditions exist, and requiring the FDA to publish facility and order request fee amounts at least 60 days before the start of each fiscal year. Finally, the bill adds as a Tier 2 OTC monograph order request a request for the addition or modification of a testing procedure applicable to a monograph drug, provided the testing procedure reflects a voluntary consensus standard with respect to pharmaceutical quality. (Requestors seeking certain kinds of changes to a monograph are awarded a period of market exclusivity if the FDA makes the requested changes; tier 2 requests are not eligible for market exclusivity.)

Congressional Research Service summary (Introduced in House), quoted unchanged (nonpartisan). Read the source.

What a vote does

PSI Sci description of the legislative step (not an opinion).

The strongest published arguments

Alternatives

Needs sources: no published alternatives yet (for example a different bill, a law instead of an amendment, or keeping current law). We only show items backed by a published source. Suggest one.

Officials and money

Sponsor: Rep. Latta, Robert E. [R-OH-5] · 3 cosponsors

Money: No cost estimate published yet. No linked contracts or vendors yet.

Sources

• Congressional Research Service summary (Introduced in House)
• Congress.gov
• Data: GovInfo BILLSTATUS bulk data (Library of Congress), BILLSTATUS-119hr4273.xml <https://www.govinfo.gov/bulkdata/BILLSTATUS/119/hr>

Record fed-us-cong119-hr4273 · catalog fed-us-congress-bills-cong119 · updated 2026-11-03 by psicol fed-bills